Foundation Medicine

Dedicated to advancing personalised healthcare
Like every person, every tumour is unique. Molecular information and genomic analysis play an increasingly important role in personalising medicine, especially for cancer patients.

Foundation Medicine is a molecular insights company that provides information to physicians and their patients through a deep understanding of the molecular changes that contribute to diseases such as cancer.

Foundation Medicine offers a full suite of comprehensive genomic profiling (CGP) assays to identify the molecular alterations in an individual patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.

In Aotearoa New Zealand, Roche’s Diagnostics division is the licensed distributor of FoundationOne®CDx and FoundationOne®Liquid CDx for patients with solid tumours, as well as FoundationOne®Heme for patients with sarcomas or haematological cancers including leukaemia, lymphoma and myeloma.

For more information please visit https://www.rochefoundationmedicine.com/#/en/international/home

General enquiries contact details:

IGENZ Ltd

Phone: 0064 9 307 3981

Email: [email protected]

Roche Diagnostics New Zealand Customer Service contact details:

Phone: 0800 652 634

Email: [email protected]

Roche Diagnostics New Zealand Ltd.

Level 1, No. 1 Sylvia Park

286 Mount Wellington Highway

Mount Wellington, Auckland 1060, New Zealand

Auckland, New Zealand

If your enquiry is related to Medical Information or reporting adverse events/product complaints, please use the following contact details:

Phone: 0800 363 622

Email: [email protected]

© 2024, Roche Products (New Zealand) Ltd, Auckland. This site is intended for New Zealand audiences. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or use in the country of your origin. Access to this site is subject to the terms in our Legal and Privacy Statement. You accept these terms by continuing to access this site.

M-NZ-00000625-v20.0/MR10379/DEC24. This site was last updated December2024.

ContactDrug SafetyWorldwide LocationslinkedinfacebooktwitterinstagramyoutubePharma solutionsRoche careersRoche cancer treatmentsRoche diagnosticsRoche hubPrivacy statementLegal statementContact UsHealthcare Professionals Portal